{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000099","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.350355+00:00","generated_at":"2026-05-28T05:10:06.443562+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure doses first patient in Phase 1 study of B7-H4 ADC LNCB74 for multiple cancers","bullets":["First patient dosed in Phase 1 study of LNCB74, a B7-H4-targeting ADC.","LNCB74 is being developed as a therapeutic for treating multiple cancers.","FDA cleared the IND for LNCB74 in December 2024.","LNCB74 is developed in partnership with LigaChem Biosciences.","Phase 1 aims to evaluate safety, tolerability, and preliminary anti-tumor activity."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000099","json":"https://secwatch.observer/filing/0001558370-25-000099.json","markdown":"https://secwatch.observer/filing/0001558370-25-000099.md","text":"https://secwatch.observer/filing/0001558370-25-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837025000099/0001558370-25-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837025000099/nxtc-20250110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:10:06.443562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}